Some 1,000 patients with a specific form of advanced breast cancer in England can, at last, receive AstraZeneca and Daiichi ...

TOKYO--Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2+ eBC ...

LONDON, Sept 17 (Reuters) - AstraZeneca and Daiichi Sankyo said on Thursday their breast cancer treatment Enhertu has been ...

A higher death risk in a phase 3 trial threatens to thwart AstraZeneca and Daiichi Sankyo’s bid to establish their star ...

AstraZeneca , the oncology and biopharmaceutical company, secured a major access win for Enhertu in England after the NHS reversed an ear ...

England’s health spending watchdog on Thursday recommended Enhertu, a breast cancer therapy developed by AstraZeneca (AZN) and Daiichi Sankyo (DSNKY) for use across the country's National Health ...

AstraZeneca stock advanced in London trading on September 18, 2026 after CEO Pascal Soriot bought 60,000 shares at GBP 121.02 ...

AstraZeneca PLC and its partner Daiichi Sankyo Co Ltd on Friday announced that their cancer drug Enhertu has been recommended to be approved in the EU for a form of breast cancer. AstraZeneca, the ...

A breast cancer drug from AstraZeneca will now be available in England after a pricing deal was reached, in part a result of ...

Trastuzumab deruxtecan is a HER2-directed antibody drug conjugate (ADC) discovered by Daiichi Sankyo and jointly developed and commercialized by Daiichi Sankyo and AstraZeneca. The treatment combines ...

Enhertu is a specifically engineered HER2-directed Dxd antibody-drug conjugate (ADC), discovered by Daiichi Sankyo and jointly developed and commercialised by AstraZeneca. It is already approved for ...

AstraZeneca PLC and Daiichi Sankyo Co Ltd on Monday reported their medicine Enhertu kept the disease from worsening for longer in patients with advanced lung cancer driven by a mutation in the gene ...